The conjugate of Trastuzumab and methylated β-cyclodextrin-threaded polyrotaxane for tumor targeting. (IMAGE)

Tokyo Medical and Dental University

The conjugate of Trastuzumab and methylated β-cyclodextrin-threaded polyrotaxane for tumor targeting.

Caption

The conjugate of Trastuzumab, a monoclonal antibody against HER2 expressed in various malignant tumors, and methylated β-cyclodextrin-threaded polyrotaxane (Me-PRX) is designed for specific delivery of Me-PRX in HER2-expressing tumor cells. Because Me-PRX is known to induce endoplasmic reticulum stress-related autophagic cell death, Trastuzumab-Me-PRX conjugates are regarded as a new class of antibody-drug conjugates that would contribute to the chemotherapy of cancers through the induction of autophagic cell death.

Credit

Department of Organic Biomaterials,TMDU

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.